Deriving joy and satisfaction from delivering new drugs as soon as possible
In Japan, mental illness is one of the “5 Major Diseases” for which measures are needed under the government’s Medical Plan. It is estimated that more people suffer from mental illness than any of the other major diseases — approximately 3,230,000 people (according to a 2008 patient survey) — and research has shown that around 90% of the approximately 30,000 people who commit suicide annually suffer from some kind of mental disorder. To address this problem there is a need for early treatment and for collaboration with local hospitals and clinics. The number of patients suffering from dementia and other kinds of neurological disorders is also expected to grow, but despite the urgency of the problem for the country and the substantial efforts made to understand mechanisms of disease development and to develop medicines, this challenge remains unconquered. On the other hand, although little or no progress has been made in elucidating the pathology and developing treatments for intractable and rare diseases, groundbreaking treatment methods utilizing new technologies are expected to be developed in the years ahead.
To contribute to society through new drug development as professionals and specialists of clinical research and development in the area of CNS (Central Nervous System), Linical has engaged in clinical trials of all kinds of diseases, focused in particular on Phase II and Phase III trials in Japan. We have won contracts from different clients covering a variety of diseases, including clinical depression, schizophrenia, sleep disorders, Parkinson’s disease, and Alzheimer’s disease. We have also worked on a wide range of other diseases, including childhood and adult ADHD, intractable diseases such as Guillain-Barré syndrome, and rare diseases such as spinal muscular atrophy. Linical’s Global Development Business Unit has also begun working on Asian joint development projects in epilepsy. In our responsible role for clinical development in the area of CNS, which is known for its high degree of difficulty, we are devoted to our work, deriving joy and satisfaction from delivering new drugs as soon as possible to relieve the suffering of patients in distress. We do this with knowledge of diseases, relevant guidelines, clinical rating scales and assessments for each disease, and with knowledge of the influence of the placebo effect for each disease and trial, and also by maintaining dialogue and communication with doctors at medical institutions.